90% Capital Reduction (10:1 Stock Consolidation) to Improve Financial Structure


  • Decided 90% capital reduction (10:1 stock consolidation) to cover deficit and improve financial structure
  • Consolidation of 10 common shares (face value 1,000 won) into 1 share; outstanding shares reduced from 71,523,533 to 7,152,353 (90% reduction)
  • Capital stock reduced from 71,523,533,000 won to 7,152,353,000 won (90% reduction)
  • Shareholder meeting scheduled on May 21, 2026; record date for reduction June 5, 2026; expected listing change June 30, 2026
  • Trading suspension from June 4 to June 29, 2026
  • Reduction passed by ordinary resolution, creditor objection procedure omitted
  • Fractional shares (less than 1) to be paid in cash based on closing price on the first day of changed listing
ADVERTISEMENT (250px+)

KOSDAQ Filing Information


  • Filing: Proxy Statement
  • Company: Telcon RF Pharmaceutical (200230)
  • Submission: Telcon RF Pharmaceutical. Inc.
  • Receipt: 04-29-2026